Histone deacetylase inhibitors: Molecular mechanisms of action

Oncogene

Volumn 26, Issue 37, 2007, Pages 5541-5552

  Xu, W S ^a   Parmigiani, R B ^a   Marks, P A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Apoptosis; Histone deacetylase; Histone deacetylase inhibitor; Mitotic cell death; Senescence

Indexed keywords

17 ALLY AMINO DEMETHOXY GELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; BACECA; BORTEZOMIB; CISPLATIN; COLECALCIFEROL; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ELLIPTICINE; EPIRUBICIN; EPOTHILONE B; ETOPOSIDE; FLAVOPYRIDOL; FLOXURIDINE; FR 901228; GELDANAMYCIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; ITF 2357; LBH 589; MGCD 0103; MIDOSTAURIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PCI 24781; PHOSPHATIDYLINOCITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PIVALOYLOXYMETHYL BUTYRATE; REACTIVE OXYGEN METABOLITE; RETINOID; SAVICOL; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CELL CYCLE ARREST; CELL DEATH; CELL HETEROGENEITY; CELL PROLIFERATION; CELL TRANSFORMATION; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GROWTH DISORDER; HUMAN; MITOSIS; MOLECULAR MECHANICS; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SENESCENCE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SOLID TUMOR; YEAST;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; SUBSTRATE SPECIFICITY;

EID: 34547864236     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210620     Document Type: Review

References (114)

1. Almenara J, Rosato R, Grant S. (2002). Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16: 1331-1343.
2. Anders MW, Dekant W. (1 994). Aminoacylases. Adv Pharmacol 27: 431-448.
3. Aoyagi S, Archer TK. (2005). Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15: 565-567.
4. Archer SY, Meng S, Shei A, Hodin RA. (1998). p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796.
5. Ashkenazi A. (2002). Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430.
6. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. (2005). Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734.
7. Bhalla KN. (2005). Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993.
8. Blander G, Guarente L. (2004). The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435.
9. Bolden JE, Peart MJ, Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
10. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W et al. (2006). HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357-3366.
11. Brown JM, Wilson WR. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
12. Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S. (2004). Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279: 7685-7691.
13. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K et al. (2005). Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104: 2717-2725.
14. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R et al. (2004). Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23: 6693-6701.
15. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170.
16. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA et al. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705.
17. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP et al. (2003). Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165-1175.
18. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M et al. (2005). Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 4: 22.
19. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS. (2005). Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887.
20. Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. (2001). Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 21: 1129-1133.
21. Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F. (2003). Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 14: 3821-3833.
22. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436.
23. Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. (2005). Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 4: 197-206.
24. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39.
25. Duvic M, Zhang C. (2006). Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 95(Suppl 1): S13-S19.
26. Fath DM, Kong X, Liang D, Lin Z, Chou A, Jiang Y et al. (2006). Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 281: 13612-13619.
27. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
28. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D et al. (2003). Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23: 8563-8575.
29. Gao L, Cueto MA, Asselbergs F, Atadja P. (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748-25755.
30. Garber K. (2007). HDAC inhibitors overcome first hurdle. Nat Biotechnol 25: 17-19.
31. Glaser KB. (2006). Defining the role of gene regulation in resistance to HDAC inhibitors - mechanisms beyond P-glycoprotein. Leuk Res 30: 651-652.
32. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. (2003). Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163.
33. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM et al. (1999). Hybrid polar hist-one deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59: 4392-4399.
34. Glozak MA, Sengupta N, Zhang X, Seto E. (2005). Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
35. Gray SG, Qian CN, Furge K, Guo X, Teh BT. (2004). Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773-795.
36. Gregoretti IV, Lee YM, Goodson HV. (2004). Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
37. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246.
38. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389-4394.
39. Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T. (2003). p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 554: 347-350.
40. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF et al. (2003). Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307: 720-728.
41. Huang L, Pardee AB. (2000). Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6: 849-866.
42. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
43. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. (2005). Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76.
44. Iwabata H, Yoshida M, Komatsu Y. (2005). Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics 5: 4653-4664.
45. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH et al. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
46. Jiang X, Wang X. (2004). Cytochrome c-mediated apoptosis. Annu Rev Biochem 73: 87-106.
47. Johnston JA, Illing ME, Kopito RR. (2002). Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 53: 26-38.
48. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. (1998). Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273: 6297-6302.
49. Kato H, Tamamizu-Kato S, Shibasaki F. (2004). Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279: 41966-41974.
50. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738.
51. Kelly W, Marks P. (2005). Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157.
52. Kim DK, Lee JY, Kim JS, Ryu JH, Choi JY, Lee JW et al. (2003a). Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J Med Chem 46: 5745-5751.
53. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. (2003b). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300.
54. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607-618.
55. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019-2028.
56. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607.
57. Lehrmann H, Pritchard LL, Harel-Bellan A. (2002). Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86: 41-65.
58. Liang D, Kong X, Sang N. (2006). Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 5: 2430-2435.
59. Lillig CH, Holmgren A. (2007). Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal 9: 25-47.
60. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. (2007). Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model B cell lymophoma. Proc Natl Acad Sci USA 104: 8071-8076.
61. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD et al. (2004). The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18: 1207-1214.
62. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R et al. (2005). Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261-309.
63. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. (2005). Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11: 8467-8475.
64. Marks PA, Breslow R. (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
65. Marks PA, Dokmanovic M. (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511.
66. Marks PA, Richon VM, Rifkind RA. (1996). Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: molecular and clinical studies employing hybrid polar compounds. Int J Hematol 63: 1-17.
67. Miller TA, Witter DJ, Belvedere S. (2003). Histone deacetylase inhibitors. J Med Chem 46: 5097-5116.
68. Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
69. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. (2004). Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545.
70. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. (2003). Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055-4062.
71. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. (2001). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492-8497.
72. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. (2004). Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271.
73. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. (2003). Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236-3239.
74. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H et al. (1999). Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650.
75. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. (2005). Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702.
76. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. (2003). Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471.
77. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949.
78. Powis G, Mustacich D, Coon A. (2000). The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322.
79. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P et al. (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1{alpha}. Cancer Res 66: 8814-8821.
80. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. (2000). Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11: 2069-2083.
81. Rascle A, Johnston JA, Amati B. (2003). Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 23: 4162-4173.
82. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003-3007.
83. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019.
84. Robbins AR, Jablonski SA, Yen TJ, Yoda K, Robey R, Bates SE et al. (2005). Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4: 717-726.
85. Rosato RR, Almenara JA, Grant S. (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637-3645.
86. Rosato RR, Grant S. (2004). Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13: 21-38.
87. Rosato RR, Grant S. (2005). Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 9: 809-824.
88. Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S et al. (2006). The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 69: 216-225.
89. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. (2001). Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 19: 181-191.
90. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. (2001). The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98: 10833-10838.
91. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. (2002). Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 99: 292-298.
92. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y et al. (1998). Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606.
93. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T et al. (2002). Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64: 1079-1090.
94. Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M et al. (2005). Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69: 603-616.
95. Shao Y, Gao Z, Marks PA, Jiang X. (2004). Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035.
96. Solit DB, Rosen N. (2006). Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6: 1205-1214.
97. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ et al. (2004). Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Cambridge) 12: 1325-1334.
98. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical genitourinary cancer 5: 57-60.
99. Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K et al. (2005). Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 203: 387-397.
100. Taddei A, Maison C, Roche D, Almouzni G. (2001). Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3: 114-120.
101. Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q. (2006). Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 281: 10508-10515.
102. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. (2005). Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678.
103. Van Lint C, Emiliani S, Verdin E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253.
104. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D et al. (2004). Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101: 15064-15069.
105. Vidal A, Koff A. (2000). Cell-cycle inhibitors: three families united by a common cause. Gene 247: 1-15.
106. Wang LG, Ossowski L, Ferrari AC. (2004). Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23: 5175-5184.
107. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. (2002). Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982-7992. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. (2006). Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103: 15540-15545.
108. Xu WS, Perez G, Ngo L, Gui CY, Marks PA. (2005). Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65: 7832-7839.
109. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. (2003). From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10: 2351-2358.
110. Zhang XD, Gillespie SK, Borrow JM, Hersey P. (2004). The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 3: 425-435.
111. Zhang Y, Gilquin B, Khochbin S, Matthias P. (2006). Two catalytic domains are required for protein deacetylation. J Biol Chem 281: 2401-2404.
112. Zhao LJ, Subramanian T, Zhou Y, Chinnadurai G. (2006). Acetylation by p300 regulates nuclear localization and function of the transcriptional corepressor CtBP2. J Biol Chem 281: 4183-4189.
113. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. (2005). Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102: 16090-16095.
114. Zou H, Wu Y, Navre M, Sang BC. (2006). Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun 341: 45-50.